The information in the press release is intended for investors.

Isofol to present at upcoming investor meetings in December

GOTHENBURG, Sweden, November 20, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate in several investor meetings during December.

Isofol is developing arfolitixorin – a proprietary clinical-stage drug candidate designed to enhance the efficacy of established cancer treatments. Based on extensive clinical research, arfolitixorin is now being tested in a phase Ib/II clinical study with an optimized dose regimen, initially conducted at the German University Hospital Charité. The drug candidate has the potential to fill a known treatment gap in cancer care.

Isofol's CEO Petter Segelman Lindqvist will present the company and the development of arfolitixorin at the following events:

- December 2, Redeye Life Science Day 2026, Stockholm
- December 2, Life Science Focus, Pharma Outsourcing – Find the right partner, Stockholm
- December 3, ABG Sundal Collier Investor Days, Stockholm
- December 8, Dagens industri Investor Summit Life Science, Stockholm

Isofol Investor & Scientific update

Last week, Isofol invited investors, shareholders, and other stakeholders to an *Investor & Scientific Update* on November 12 and 13 in Stockholm and Gothenburg. Recordings of the presentations are available on the company's website, www.isofolmedical.com.

For more information, please contact

Isofol Medical AB (publ)
Jenny Brinkeby, Investor relations & marketing coordinator
E-mail: jenny.brinkeby@isofolmedical.com
Phone: +46 (0)31 13 73 31

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on November 20, 2026.

About Isofol

Isofol Medical AB (publ) is a clinical stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. The company's drug candidate arfolitixorin, a next generation folate treatment, is designed to enhance the efficacy of established standard treatments for several types of solid tumors. Arfolitixorin is currently being evaluated in phase Ib/II in colorectal cancer, the world's third most common cancer, where there is a significant unmet medical need. Isofol is listed on Nasdaq Stockholm.

www.isofolmedical.com